• Home |
• Contacts |
• Links |
• Quality Standards |
• Instructions for Use |
• Careers

08 November 2005

Oxoid Demonstrate Their Expertise in Pharmaceutical Microbiology at Pharmig Annual Conference

Colin Booth, Vice President Science & Technology at pharmaceutical microbiology experts, Oxoid Ltd, will be giving a presentation at the PharMIG Annual Conference (22-23 November 2005, Oxford Belfry Hotel, UK) on “Current Methods of Microbial Identification”. The agenda for this presentation which will take place during the afternoon of 22 November is:

• Taxonomic changes – an update.
• Your identification methods give answers, but are they the correct ones?
• Your customer is not a microbiologist – try reporting identification results in a language they understand.
• Viable non-culturable micro-organisms – who cares?
• A review and comparison of the best methods of identification.

Oxoid representatives will also be available to provide information on Oxoid’s many products for the pharmaceutical industry including the RiboPrinter® Microbial Characterisation System, which is available from Oxoid in Europe and Australia. The RiboPrinter® Microbial Characterisation System is useful in many applications, including strain-level identification, pinpointing sources of contamination, clinical trial support, research and development, and ensuring culture integrity. It also allows compliance with the US Food and Drug Administration (FDA) Code of Federal Regulations for electronic record security (21 CFR Part 11). For pharmaceutical, biotechnical and other FDA-regulated industries, 21 CFR Part 11 compliance is essential for any system that stores data. The RiboPrinter® system stores all information about an analysed isolate, including the ribotype fingerprint, links to any information associated with that pattern, an accurate history of data changes, the source of the isolate, and any additional presumptive identification information obtained.

For more information please contact Val Kane, tel: +44 (0) 1256 841144, fax: +44 (0) 1256 329728, email pharma@oxoid.com.